
Ex. 5 Deliberative Process (DP) HOT TOPICS Ex. 5 Deliberative Process (DP)



implementing the 2020 revisions. This preliminary injunction is in effect until June 18, 2021, but it could be extended as the litigation is ongoing.

PBTs and PIP 3:1 - In March, EPA announced a 60-day comment period (ending May

17) to collect additional input on the 5 final PBT rules that were issued on January 6. EPA also issued a temporary 180-day "No Action Assurance" indicating that the agency will exercise its enforcement discretion regarding the prohibitions on processing and distribution of PIP (3:1) for use in articles, in order to ensure that the supply chain is not interrupted while EPA continues to collect the information needed to inform subsequent regulatory efforts.

Seresto Pet Products - Since its registration in 2012, there have been over 86,000 incident reports on the Seresto dog and cat pet collar, which is designed to kill fleas, ticks and lice and contains the active ingredients flumethrin and imidadoprid. EPA is actively working with the registrant to further understand the full context of the incidents and will be issuing a directive to the company to provide additional information to better characterize the nature and scale of the incident reports. Our analysis of the incidents is actively underway, and we will take appropriate action after completing our assessment of the incidents. We plan to collaborate with experts from other regulatory authorities in our analyses of the incident data. EPA sent letters to Elanco and Bayer, the current and former registrants for Seresto pet collars, reiterating their legally required duty under FIFRA to provide the Agency with information regarding unreasonable adverse effects for their registered pet products. We will review the additional information and use it to evaluate if the continued registration of these pet collars still meets the legally required standard of no unreasonable adverse on the environment.

Safer Choice - Committed to rebuilding the Safer Choice and P2 programs because they play critical roles in protecting human health and the environment. Our pollution prevention efforts demonstrate meaningful opportunities for successful implementation of exposure reduction efforts and complement our risk management efforts under TSCA.

Formatted: Font: 12 pt

Formatted: Font: 12 pt, Strikethrough

Commented [FM13]: Why are we not mentioning the letter? I don't need this level of detail or a technical summary. I need words to describe the letter and something more message-oriented.

Commented [DD14R13]: See new language in red.

Formatted: Font: 12 pt, Strikethrough

Formatted: Font color: Auto

Formatted: Font: 12 pt, Font color: Auto

Formatted: Font: 12 pt

Commented [FM15]: Don't need this

Formatted: Font: 12 pt

Formatted: Font: 12 pt